Haematology

Guidelines (11)

Ibrutinib with Bendamustine and Rituximab for Treating Relapsed or Refractory Chronic Lymphocytic Leukaemia after Systemic Therapy (terminated appraisal) (TA437)

22 March 2017

Dasatinib, Nilotinib and Imatinib for Untreated Chronic Myeloid Leukaemia (TA426)

3 January 2017

Dasatinib, Nilotinib and High-Dose Imatinib for Treating Imatinib-Resistant or Intolerant Chronic Myeloid Leukaemia (TA425)

3 January 2017

Pegaspargase for Treating Acute Lymphoblastic Leukaemia (TA408)

28 September 2016

Bosutinib for Previously Treated Chronic Myeloid Leukaemia (TA401)

24 August 2016

Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30% Bone Marrow Blasts (TA399)

27 July 2016

Erythropoiesis‑Stimulating Agents (Epoetin and Darbepoetin) for Treating Anaemia in People with Cancer Having Chemotherapy (TA323) (including review of TA142)

26 November 2014

Bosutinib for Previously Treated Chronic Myeloid Leukaemia (TA299)

27 November 2013

Eltrombopag for Treating Chronic Immune (Idiopathic) Thrombocytopenic Purpura (TA293 [Review of TA205])

24 July 2013

Romiplostim for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (TA221)

28 April 2011

Tables (1)

Table: Oral Iron Supplements for Iron-Deficiency States

18 October 2017

Formulations, strengths, doses and costs of iron supplements.

Drug Sections (13)

Haematology in the News

Risk of serious skin reactions with anaemia drugs

By Chloe Harman, 26 October 2017

Severe cutaneous adverse reactions can occur in patients...

Rituximab biosimilar launched in UK

By Chloe Harman, 3 April 2017

Oral Iron Supplements for Iron-Deficiency States

27 March 2017